课题基金 / 基金详情

Development of Intact Proviral DNA Assays for SIV and SHIV

Development of Intact Proviral DNA Assays for SIV and SHIV
SIV 和 SHIV 完整原病毒 DNA 检测的开发
批准号:
9907751
负责人:
Gregory Michael Laird
金额:
$30.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-12-12 至 2021-11-30

项目摘要

项目成果

Gregory Michael Laird的其他基金

相似基金

相关文献

中文摘要
翻译
项目摘要/摘要 人类免疫缺陷病毒1型(HIV-1)是一种逆转录病毒,感染免疫的CD4+T细胞 系统。如果不进行治疗,HIV-1感染者将发展为艾滋病,并可能最终死亡。 联合抗逆转录病毒疗法在阻止HIV-1在感染者体内复制方面极其有效 个人。尽管这种疗法成功地将HIV-1复制抑制到临床无法检测的水平, 抗逆转录病毒疗法是不能治愈的。这是由于HIV-1在体内持续处于沉默或潜伏状态 CD4+T细胞的一个亚群,称为静息记忆的CD4+T细胞。在这种潜伏状态下,这些被感染的细胞不是 是抗逆转录病毒药物的靶点,不能被免疫系统消除。在HIV-1感染者中, 潜伏感染的CD4+T细胞以极低的频率被发现(每百万个静止记忆中约有1个 细胞),在任何给定的时间,大多数存在于免疫组织中。这群潜伏感染的细胞 非常稳定,要求HIV-1感染者无限期地继续接受抗逆转录病毒治疗,以避免 病毒血症反弹。因此,这种潜伏感染的CD4+T细胞是治愈HIV-1的主要障碍 感染。 开发消除潜伏感染细胞的策略是NIH、NIAID和HIV- 1研究领域。SIV和/或SIV感染猕猴是研究HIV的关键的非人类灵长类动物模型。 1坚持和测试新的治疗方法。有效展示应聘者的效能 针对这些动物中的潜伏性蓄水池的治疗,我们必须能够测量潜伏期 感染的细胞使用快速和准确的分析方法,可以按比例广泛使用,可以进行分析 外周血液和加工过的组织,并可转化为人类临床研究。阿卡利韦 因此,LLC正在与约翰霍普金斯医学院的Siliciano实验室合作开发 SIV和SIV适应的完整前病毒DNA分析(IPDA)和相应的对照用于这些关键的 动物研究。总的来说,该提案旨在为SIV IPDA开发和表征新的细胞系控制 和SHIV IPDA,鉴定SIV IPDA和SHIV IPDA的性能,并执行初步评估 IPDA作为SIV/SIV感染猕猴治疗干预研究中的药效学生物标志物。
英文摘要
PROJECT SUMMARY/ABSTRACT Human immunodeficiency virus type-1 (HIV-1) is a retrovirus that infects CD4+ T cells of the immune system. If left untreated, HIV-1 infected individuals will progress to AIDS and may ultimately die as a result. Combination antiretroviral therapy is extremely effective at stopping the replication of HIV-1 in infected individuals. Despite the success of this therapy at suppressing HIV-1 replication to clinically undetectable levels, antiretroviral therapy is not curative. This is due to the persistence of HIV-1 in a silent, or latent, state within a subset of CD4+ T cells known as resting memory CD4+ T cells. In this latent state, these infected cells are not targeted by antiretroviral drugs and cannot be eliminated by the immune system. In HIV-1 infected individuals, latently infected CD4+ T cells are found at extremely low frequencies (~1 per million resting memory CD4+ T cells), with the majority found within immune tissues at any given time. This population of latently infected cells is very stable, demanding that HIV-1 infected individuals remain on antiretroviral therapy indefinitely to avoid rebound of viremia. As such, this population of latently infected CD4+ T cells is the main barrier to curing HIV-1 infection. Developing strategies to eliminate latently infected cells is a major focus of the NIH, NIAID, and the HIV- 1 research field. SIV and/or SHIV infected macaques are a critical non-human primate model for studying HIV- 1 persistence and testing novel therapeutic approaches. To effectively demonstrate the efficacy of candidate therapeutics targeting the latent reservoir in these animals, we must be able to measure the frequency of latently infected cells using rapid and accurate assays that can be scaled for widespread use, are amenable to analyzing both peripheral blood and processed tissues, and can be translated to human clinical studies. Accelevir Diagnostics, LLC is therefore working with the Siliciano lab at Johns Hopkins School of Medicine to developing SIV and SHIV adapted intact proviral DNA assays (IPDA) and corresponding controls for use in these critical animal studies. Broadly, the proposal aims to develop and characterize novel cell line controls for the SIV IPDA and SHIV IPDA, qualify the performance of the SIV IPDA and SHIV IPDA, and perform initial evaluation of the IPDA as a pharmacodynamic biomarker in SIV/SHIV infected macaque studies of curative interventions.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
IPDA for High-Priority HIV-1 Subtype C to Enable Global Eradication Trials
  • 批准号:
    10445356
  • 项目类别:
  • 资助金额:
    $30.0万
  • 财政年份:
    2021
  • 负责人:
    Gregory Michael Laird
  • 依托单位:
HIV-1 EnvLRS: a scalable, sequence-based assay for in-depth assessment of HIV-1 bNAb resistance
  • 批准号:
    10324540
  • 项目类别:
  • 资助金额:
    $30.0万
  • 财政年份:
    2021
  • 负责人:
    Gregory Michael Laird
  • 依托单位:
IPDA for High-Priority HIV-1 Subtype C to Enable Global Eradication Trials
  • 批准号:
    10324486
  • 项目类别:
  • 资助金额:
    $30.0万
  • 财政年份:
    2021
  • 负责人:
    Gregory Michael Laird
  • 依托单位:
Centralized Resource to Accurately Quantify Latent and Expressed HIV Reservoirs
  • 批准号:
    10378515
  • 项目类别:
  • 资助金额:
    $116.79万
  • 财政年份:
    2020
  • 负责人:
    Gregory Michael Laird
  • 依托单位:
海外基金